Aurelia Butler

LONDON/COPENHAGEN(Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company’s ambitions for a successor to its Wegovy weight-loss drug that is more powerful than Eli Lilly (NYSE:LLY)’s rival Zepbound, also known as Mounjaro.Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk (NYSE:NVO) had expected.Novo’s share price fell as much as 27% after the results were announced, hitting their lowest since August 2023 in one of the biggest one-day wipe outs on record for a European company. They were down 18.8% at 1225 GMT.Shares in U.S. rival Lilly rose more than 7% in pre-market trade.’WORST CASE SCENARIO’ Novo said if all people adhered to treatment with CagriSema, patients overall achieved weight loss of 22.7% after 68 weeks, with 40.4% losing 25% or more.The results are a “worst case-scenario” for Novo, said Markus Manns, portfolio manager at mutual funds firm Union Investment, a Novo and Lilly shareholder.”CagrisSema is only as good as Zepbound, but more complex to manufacture,” he said.Lilly’s own obesity injection – sold as Zepbound in the United States – led to an average weight loss of nearly 23% in clinical trials.The data from Novo’s CagriSema Phase III trial was based on about 3,400 people with a body mass index (BMI) of 30 or above or people with a BMI of 27 and at least one weight-related comorbidity like hypertension or cardiovascular disease.Martin Holst Lange, Novo Nordisk’s executive vice president for development, said Novo was “encouraged” by the data. He said only 57% of patients in the trial reached the highest dose.The company did not immediately respond to a request for comment on why more patients did not reach the highest dose.Novo Nordisk plans to start a new trial in the first half of next year to further explore CagriSema’s additional weight-loss potential, a Novo Nordisk spokesperson said. It expects to submit the drug for regulatory approval towards the end of 2025.Novo said the drug had similar side effects compared with its GLP-1 drugs already on the market. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class, it said.WEEKLY INJECTIONCagriSema is a weekly injection which combines semaglutide, which is the active ingredient in Wegovy and mimics the gut hormone GLP-1, and a separate molecule called cagrilintide that mimics the pancreatic hormone amylin, into a weekly injection.The two hormones combined suppress hunger and help control patients’ blood glucose.Novo’s trial is the most advanced for an amylin drug candidate currently being tested in the market.The success of Wegovy helped make Novo Europe’s biggest company by market capitalisation, worth more than $460 billion.Its shares have been under pressure this year, however, significantly underperforming those of chief rival Lilly, due mainly to concerns Novo may be losing its first-mover advantage in the obesity drug race. More

According to LSEG Lipper data, investors divested a net $37.22 billion worth of global equity funds in the week, the largest amount for a single week since September 2009.The Fed cut rates as expected on Wednesday and signaled fewer rate cuts and projected higher inflation for next year, prompting a sell-off in global equities after Chair Jerome Powell emphasized the need for caution.The MSCI World index has declined more than 3% this week and is set for its sharpest weekly fall in three and a half months.Investors offloaded a robust $50.2 billion worth of U.S. equity funds, logging the biggest weekly net sales since September 2009. European and Asian funds, however, experienced $9.21 billion and $1.74 billion worth of net purchases.Meanwhile, global sectoral funds experienced their largest weekly outflow in 14 weeks, totaling $2.65 billion, with the tech and healthcare sectors facing net disposals of $1.37 billion and $737 million respectively.Global bond funds continued to attract investor interest for a 52nd consecutive week, securing about $2.36 billion in net purchases, albeit the lowest amount in eight months. Corporate and loan participation funds drew substantial inflows of $2.01 billion and $1.12 billion, respectively. Meanwhile, government bond funds experienced $594 million in outflows, marking a third consecutive week of net sales.Money market funds recorded about $51.02 billion in net sales, marking the fourth outflow in five weeks. In the commodities sector, gold and precious metal funds saw $1.67 billion withdrawn, the largest since July 2022, while energy funds experienced $215 million in outflows.According to data covering 29,603 funds, emerging market equities faced increased selling pressure, with equity funds recording their sharpest net outflow in about a year at $5.27 billion, and bond funds also seeing $710 million in net outflows. More

Fed Chair Jerome Powell said more reductions in borrowing costs now hinge on further progress in lowering stubbornly high inflation, remarks that showed policymakers are starting to reckon with the prospects for sweeping economic changes under a Trump administration.Here are the forecasts from major brokerages for 2025:Rate cut estimates (in bps) Brokerages Jan 2025 2025 Fed Funds Rate BofA Global No rate cut 50 3.75%-4.00% (end of Research June) Barclays (LON:BARC) No rate cut 50 3.75%-4.00% (end of 2025) Goldman Sachs No rate cut 75 (through 3.50%-3.75% (through September September 2025) 2025) J.P.Morgan No rate cut 75(through 3.75% (through September September 2025) 2025) 3.375% (Q4 2025) Morgan Stanley (NYSE:MS) No rate cut 50 (through June 2025) Nomura No rate cut 25 4.00%-4.25% (through end of 2025) *UBS Global No rate cut 125 3.00%-3.25% (through Research end of 2025) Deutsche Bank (ETR:DBKGn) No rate cut No Rate 4.25%-4.50% Cuts Societe No rate cut – 3.00%-3.25% (by Generale early 2026) ING No rate cut 75 3.75% – 4.00% Macquarie No rate cut 25 4.00%-4.25% UBS Global No rate cut 50 3.75%-4.00% (end of Wealth 2025) Management Peel Hunt No rate cut 50 3.50%-4.00% * UBS Global Research and UBS Global Wealth Management are distinct, independent divisions in UBS Group More

The Fed cut rates as expected on Wednesday but projected fewer-than-expected interest rate cuts and higher inflation next year, while Chair Jerome Powell explicitly referred a need for caution, prompting a sell-off in equity markets.Investors withdrew a hefty $20.93 billion from U.S. large-cap funds, halting a six-week-long streak of net purchases. They also shed small-cap, multi-cap and mid-cap funds to the tune of $5.41 billion, $3.91 billion and $2.85 billion, respectively.U.S. sectoral funds recorded net sales for the third consecutive week, totaling $1.53 billion, with the tech and healthcare sectors leading the outflows at $1.32 billion and $324 million, respectively. Meanwhile, the financial sector attracted $578 million in net purchases during the same period.For the first time in 29 weeks, U.S. debt funds experienced a drop in demand, with investors withdrawing a net $2.1 billion. Specifically, U.S. government bond funds faced the largest weekly outflow since October 2, amounting to $2.23 billion. General domestic taxable fixed income and loan participation funds received inflows of $2.08 billion and $1.01 billion, respectively.U.S. money market funds witnessed a fourth weekly outflow in five weeks, to the tune of $28.07 billion. More

(Reuters) -U.S. stock index futures dove on Friday as investors grappled with the possibility of a government shutdown and a higher interest rate path ahead of a key inflation report due on the day.Dozens of Republicans defied President-elect Donald Trump’s spending bill, leaving Congress with no clear plan before government funding expires at midnight. Failure to extend the deadline could disrupt holiday travel.Trump’s plans on tariffs, tax cuts and deregulation were among the factors that pushed the Federal Reserve to raise its 2025 forecast for inflation and halve the central bank’s projections of rate cuts that slammed Wall Street on Wednesday.”We doubt there will be a new agreement in time to avert a partial shutdown after December 20, but we expect a new spending bill around the end of the year,” Paul Christopher, head of global investment strategy at Wells Fargo (NYSE:WFC) Investment Institute, said in a note.”Even if a shutdown occurs, we believe there is likely to be little economic or financial-market impact.” Data-wise, investors will look to the Commerce Department’s personal consumption expenditure (PCE) report, due at 8:30 a.m. ET, for clues on how inflation will guide the Fed’s policy. The data is expected to show U.S. consumer spending rose 0.2% last month, the same pace as October.Traders currently expect fewer than two U.S. rate cuts by the end of next year after the central bank lowered rates by a quarter point as expected this week.Comments from San Francisco Fed President Mary Daly are also on the radar, ending the media blackout period Fed policymakers had entered ahead of Wednesday’s decision. At 6:52 a.m. ET, Dow E-minis were down 186 points, or 0.44%, S&P 500 E-minis were down 52 points, or 0.88% and Nasdaq 100 E-minis were down 305.25 points, or 1.43%. The Nasdaq was set to fall for the first time in five weeks and the S&P 500 was on pace for its worst week since September. The Dow was on track for its sharpest weekly fall since March 2023.Investors are expecting more gains for the stock market in 2025, fueled by a solid economy supporting corporate profits, moderating interest rates and pro-growth policies from incoming President Donald Trump.Elsewhere, European stocks dropped as Trump threatened to hit the European Union with tariffs if the bloc does not make large oil and gas trades.Most megacap and growth stocks were lower in premarket trading, with Tesla (NASDAQ:TSLA) down 5.2% and Nvidia (NASDAQ:NVDA) and Amazon.com (NASDAQ:AMZN) off 3.1% and 2.6% respectively. Nike (NYSE:NKE) dropped 4.4% after the sportswear seller forecast revenue would fall by low double-digits in the third quarter.FedEx (NYSE:FDX) jumped 9.5% after announcing the much-anticipated spinoff of its freight trucking division, as it restructures operations to focus on its core delivery business.Eli Lilly (NYSE:LLY) advanced 9.6% after Danish rival Novo Nordisk (NYSE:NVO)’s experimental next-generation obesity drug achieved lower-than-expected weight loss in a late-stage trial. Other weight-loss drug developers also gained, with Amgen (NASDAQ:AMGN) up 4.3% and Viking Therapeutics (NASDAQ:VKTX) soaring 16.9%. More

$75 per monthComplete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.What’s included Global news & analysisExpert opinionFT App on Android & iOSFT Edit appFirstFT: the day’s biggest stories20+ curated newslettersFollow topics & set alerts with myFTFT Videos & Podcasts20 monthly gift articles to shareLex: FT’s flagship investment column15+ Premium newsletters by leading expertsFT Digital Edition: our digitised print edition More